Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
about
Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytesA new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanomaAdoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaHuman neoplasms elicit multiple specific immune responses in the autologous hostA gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytesIdentification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytesThymic selection generates a large T cell pool recognizing a self-peptide in humansHuman tumor antigens recognized by T lymphocytesTumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccinesClinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cellsTransfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategyT cell avidity and tumor recognition: implications and therapeutic strategies.Therapeutic cancer vaccines: past, present, and futureRecombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.Structures of MART-126/27–35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell RecognitionGerm Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell ReceptorStructural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cellsT-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen TargetingDNA vaccine for cancer immunotherapyExpression of tumor-rejection antigens in gynecologic cancersCytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptideSerine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patientsCleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patientsExpression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patientsGeneration of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML TechnologyClonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patientsMass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines.Melanoma Peptide Vaccines.Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteinsMelan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.Tumor antigens and tumor vaccines: peptides as immunogens.Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities.Vitiligo puzzle: the pieces fall in place.Selected climatic variables and blood pressure in Central European patients with chronic renal failure on haemodialysis treatment.Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.Clinical implications of the new biology in the development of melanoma vaccines.B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment
P2860
Q22009435-7560BEC4-BB7F-494D-ACFE-3F84F3C7CE20Q24307739-8630AE6E-0B03-4783-98B1-36C7F2314EB0Q24548019-6F2C657E-D07F-4221-93E8-2E5A9106CCD6Q24564371-44C25F06-0FFB-41B8-AF4A-7967D3627865Q24647420-53CAC219-1634-44B9-91C6-3A2E0AD1360EQ24647904-F930F713-3684-4349-9843-43415BD938ADQ24675080-9754B787-3D69-4466-A905-F71C5B985A83Q24678508-4FF8182D-0680-499E-B24A-B7054DC94278Q24804837-7A3A402E-A1D1-4CD9-9C69-685B135846BBQ24804892-A041B157-28E4-4369-9687-C2E2BFCEA6D9Q24814910-99E5C10A-BDBF-407D-86B1-DDB6540C9F4AQ24815775-3ED8ADA1-B6AA-47AA-9480-061BF773A2CDQ26863283-7BC337E6-D346-41E2-A662-E6C6B44C28B3Q27469314-770B8749-C82D-49E7-B2CA-D551FC92A142Q27647534-4B0E9F95-57E7-42E2-9CFA-7C291A8FF3E7Q27656470-CA6B3E6A-FCD3-47B6-B03D-9018FDD9DF6AQ27660843-6E3A4F67-C441-47F6-864A-0127AE5968AEQ27672418-1DA9D23C-A16B-47E4-A401-54C57597D696Q28080919-D1DD2639-1E2E-4FC8-8E00-EDEC30089E89Q28138549-2BC369C5-53B3-491F-A3C5-64DE80A33C05Q28146219-439C9BD9-D351-40AB-97F7-7AD54EC4DBC5Q28202640-4683F5B3-8049-4914-AC89-81CC51A34F1FQ28216625-9E4C687F-6C7E-42D4-8437-424F75E4849AQ28361963-3DC53AFF-1C29-41B0-A44E-40E109DA9A2AQ28551218-E63C415A-DCB9-430C-BE63-30912888DA82Q28742878-5EB3ED09-5116-4B1A-BF17-3E4FEF3AF010Q30304153-A99778F0-C75B-48C4-906E-40D0BCFC4B95Q30304290-C07646A5-84F1-47BF-9FB8-7503AA9BA539Q30305778-0CE415F4-5344-4814-894C-090F6C5FBBEDQ30371547-B541D5C6-0D5E-4565-ABE7-BCAC6B8C5947Q30442847-35E24A30-818B-4CA4-A8A2-78615EE7AA59Q30454278-4E15B323-1AD0-4F16-AEE3-08BB4D8AA8F9Q30469630-AA3B8C6B-43B3-4184-AADA-295710B9B790Q30843481-6C6268EF-B0F6-4201-911B-32DFAEE8EC89Q30863574-99B5C225-66E8-49B8-8A3A-441835D70EFAQ33344607-045E2771-8776-407B-B306-C5147C076BB6Q33433723-675BADB4-D59D-4580-83BB-131695ED7D7BQ33541549-8A873EAC-07E4-48BA-8F1B-E8855ABD7043Q33603062-EEA43D14-29FD-46F5-82FD-53A5077A9D0CQ33632113-DC1ECB2D-A6AD-496D-8FEE-E3024169F703
P2860
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Identification of the immunodo ...... umor infiltrating lymphocytes.
@ast
Identification of the immunodo ...... umor infiltrating lymphocytes.
@en
type
label
Identification of the immunodo ...... umor infiltrating lymphocytes.
@ast
Identification of the immunodo ...... umor infiltrating lymphocytes.
@en
prefLabel
Identification of the immunodo ...... umor infiltrating lymphocytes.
@ast
Identification of the immunodo ...... umor infiltrating lymphocytes.
@en
P2093
P2860
P356
P1476
Identification of the immunodo ...... umor infiltrating lymphocytes.
@en
P2093
Kawakami Y
Rivoltini L
Robbins PF
Rosenberg SA
Sakaguchi K
Yannelli JR
P2860
P304
P356
10.1084/JEM.180.1.347
P407
P577
1994-07-01T00:00:00Z